Technology | March 28, 2014

FDA Clears World’s First Implantable Sensor to Measure Radiation Dose Directly at Tumor Site

VeriTeQ’s radiation dosimetry products already have six FDA clearances and CE approvals

Q Inside SmartMarker Vertiq Corp. Radiation Dose Management Radiation Therapy

March 28, 2014 — VeriTeQ Corp. is rebranding its Q Inside SmartMarker to lead its radiation dosimetry business. Q Inside SmartMarker (previously known as DVS SmartMarker) is the only U.S. Food and Drug Administration (FDA)-cleared implantable radio frequency (RF) radiation sensor that provides localization of a tumor and measures radiation dose at the tumor site. VeriTeQ’s radiation dosimetry products have six FDA clearances and CE approvals, and the company has more than 100 patents, patents pending and exclusive licenses.

Q Inside SmartMarker is an FDA-cleared, implantable radiation sensor for use in breast and prostate cancer patients undergoing photon external beam treatments. It is implanted in, or adjacent to, solid-mass tumors and gathers data on the actual dose of radiation being delivered to the tumor and surrounding normal tissue. Q Inside SmartMarker is intended to be used in the balancing between delivering maximum dose to the tumor while minimizing the impact to healthy tissue. The sensor can confirm the treatment is conforming to the physician’s plan, as even a small deviation from planned dose can have a significant impact on patient survival rates.

Scott R. Silverman, chairman and CEO of VeriTeQ, stated, “Radiation under-dosing and, perhaps more importantly, radiation overdosing have been a top concern of the medical community for years. Confirming the delivered dose of radiation is known to have a direct and significant impact on treatment efficacy and patient survival rates, and our Q Inside SmartMarker can support healthcare providers with this potentially life-saving data.”

According to the ECRI Institute, radiation or computed tomography (CT) overdose make the list of the Top 10 Technology Hazards each year going back at least eight years. These hazards include radiation overdose and other errors during radiation therapy; unnecessary exposures and radiation burns from diagnostic radiology procedures; and exposure hazards from radiation therapy and CT.

Q Inside SmartMarker is compatible with a variety of commercially available systems including, but not limited to, CyberKnife System, Varian kV Trilogy System, TomoTherapy, Siemens MV CBCT and Resonant Medical.

For more information: www.veriteqcorp.com

Related Content

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" will be presented by Par
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
Infinitt Adds Organ Dose Data to Radiation Dose Management Solution
Technology | Radiation Dose Management | October 10, 2017
October 10, 2017 — Infinitt announced that its DoseM web-based...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Overlay Init